Obsessive-Compulsive Disorder Market Report 2025

This Obsessive-Compulsive Disorder market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

The obsessive-compulsive disorder market size has grown strongly in recent years. It will grow from $0.62 billion in 2024 to $0.67 billion in 2025 at a compound annual growth rate (CAGR) of 8.64%. The growth during the historic period was driven by factors such as an increase in early diagnosis, a rising prevalence of mental health conditions, the expanded use of cognitive behavioral therapy (CBT), improved access to online therapy, and the development of personalized treatment plans.

The obsessive-compulsive disorder market size is expected to see strong growth in the next few years. It will grow to $0.93 billion in 2029 at a compound annual growth rate (CAGR) of 8.38%. In the forecast period, growth is expected to be propelled by a rising prevalence of OCD, increasing demand for off-label drugs and therapies, heightened investment in the healthcare sector, growing awareness campaigns, and enhanced government initiatives. Key trends anticipated during this period include advancements in technology, the integration of digital health tools, the use of virtual reality in treatment, the expansion of telehealth services, and the continued adoption of cognitive behavioral therapy.

The increasing prevalence of mental illness is projected to drive growth in the obsessive-compulsive disorder (OCD) market. Mental illnesses encompass a broad spectrum of conditions that impact mood, thinking, behavior, and overall functioning. Their rise is attributed to greater awareness and diagnosis, lifestyle shifts, chronic stress, global crises, and escalating social, economic, and environmental pressures. OCD serves as a focal point for understanding the complexities of mental illnesses, advancing research, diagnosis, and treatment methods for various mental health conditions. For example, in September 2024, the National Institutes of Health (NIH) reported that in 2022, 59.3 million U.S. adults (23.1% of the population) experienced AMI (Any Mental Illness), with a higher prevalence among females (26.4%) compared to males (19.7%). This growing prevalence highlights the expanding demand for OCD-related treatments, boosting the market's growth.

Companies in the OCD market are innovating mental health treatment to deliver more effective therapeutic options. These treatments include a range of therapies, medications, and lifestyle interventions aimed at managing and alleviating mental health conditions. In October 2023, Newport Healthcare introduced a specialized OCD Treatment Program for teens and young adults. This initiative addresses the developmental and psychological needs of younger individuals with OCD and related disorders. By employing evidence-based therapies such as Cognitive Behavioral Therapy (CBT), Exposure and Response Prevention (ERP), and family-centered approaches, the program ensures accessible, holistic care. It integrates mental health treatment with mindfulness practices, physical wellness, and life skills training to promote comprehensive recovery.

In August 2023, Talkiatry partnered with NOCD to revolutionize OCD treatment through integrated services. This collaboration aims to enhance patient outcomes by combining NOCD's specialized ERP therapy with Talkiatry's psychiatric care expertise. NOCD, a U.S.-based mental health technology company, specializes in online therapy for OCD, making this partnership a strategic move to improve accessibility and streamline OCD care.

Major players in the obsessive-compulsive disorder market are Pfizer Inc., Merck & Co. Inc., Abbott Laboratories, Novartis AG, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Otsuka Pharmaceutical Co. Ltd., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Hetero Labs Limited, Sun Pharmaceutical Industries Ltd., Cipla Limited, Hikma Pharmaceuticals PLC, Dr. Reddy's Laboratories Ltd., Aurobindo Pharma Limited, Zydus Cadila, Amneal Pharmaceuticals Inc., Mallinckrodt plc, Lupin Pharmaceuticals Inc., Par Pharmaceutical, Biohaven Pharmaceuticals.

North America was the largest region in the obsessive-compulsive disorder market in 2024. The regions covered in obsessive-compulsive disorder report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the obsessive-compulsive disorder market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Obsessive-compulsive disorder (OCD) is a mental health condition characterized by persistent, intrusive thoughts (obsessions) and repetitive behaviors or mental acts (compulsions) performed to alleviate anxiety. These behaviors often disrupt daily functioning and cause significant emotional distress. Common themes include concerns about cleanliness, orderliness, and fear of harm. Treatment generally involves a combination of therapy and medication.

The primary drug classes for OCD treatment include selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), serotonin antagonist and reuptake inhibitors (SARIs), and tricyclic antidepressants (TCAs). SSRIs, a commonly prescribed class, function by increasing serotonin levels in the brain and preventing its reabsorption into nerve cells. These medications are also indicated for other conditions such as major depressive disorder, anxiety disorders, and attention deficit hyperactivity disorder (ADHD). The distribution channels for these drugs include hospital pharmacies, retail pharmacies, and other outlets, serving end users such as hospitals, specialty clinics, and other healthcare facilities.

The obsessive-compulsive disorder market research report is one of a series of new reports that provides obsessive-compulsive disorder market statistics, including obsessive-compulsive disorder industry global market size, regional shares, competitors with a obsessive-compulsive disorder market share, detailed obsessive-compulsive disorder market segments, market trends and opportunities, and any further data you may need to thrive in the obsessive-compulsive disorder industry. This obsessive-compulsive disorder market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The obsessive-compulsive disorder market includes revenues earned by entities by providing services such as diagnosing, treating, and managing mental health conditions and related products including benzodiazepines, neurostimulation devices, and ERP therapy tools. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.